CN103974948B - 在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑 - Google Patents
在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑 Download PDFInfo
- Publication number
- CN103974948B CN103974948B CN201280059851.2A CN201280059851A CN103974948B CN 103974948 B CN103974948 B CN 103974948B CN 201280059851 A CN201280059851 A CN 201280059851A CN 103974948 B CN103974948 B CN 103974948B
- Authority
- CN
- China
- Prior art keywords
- indazol
- pyrimidin
- pyridin
- methoxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(*)(C=C1)C=Cc2c1c(-c1ncc(*)c(N(*)C3=CC(C)(*)C=NC=C3)n1)n[n]2 Chemical compound CC(*)(C=C1)C=Cc2c1c(-c1ncc(*)c(N(*)C3=CC(C)(*)C=NC=C3)n1)n[n]2 0.000 description 5
- JPGFBAQQOMFHSU-CYOXGAJESA-N C/C=C(\C=C/N=C)/Nc1nc(-c2n[n](Cc(c(Cl)c3)ccc3C(O)=O)c3ccccc23)ncc1OC Chemical compound C/C=C(\C=C/N=C)/Nc1nc(-c2n[n](Cc(c(Cl)c3)ccc3C(O)=O)c3ccccc23)ncc1OC JPGFBAQQOMFHSU-CYOXGAJESA-N 0.000 description 1
- NCTZNHOZLKQUAG-UHFFFAOYSA-N CC1NC(c2n[n](Cc3ccccc3F)c3ccccc23)=NC(Cl)=C1N Chemical compound CC1NC(c2n[n](Cc3ccccc3F)c3ccccc23)=NC(Cl)=C1N NCTZNHOZLKQUAG-UHFFFAOYSA-N 0.000 description 1
- WNUWUKFVJYYGLJ-UHFFFAOYSA-N COc(cc1)c(Nc(ccnc2)c2C#N)nc1-c1n[n](Cc(cccc2)c2F)c2ccccc12 Chemical compound COc(cc1)c(Nc(ccnc2)c2C#N)nc1-c1n[n](Cc(cccc2)c2F)c2ccccc12 WNUWUKFVJYYGLJ-UHFFFAOYSA-N 0.000 description 1
- GUJXAQIBCNRTSK-UHFFFAOYSA-N COc1ccc(C[n](c2ccccc22)nc2-c(nc2Nc3ccncc3)ncc2OCC(F)(F)F)cc1 Chemical compound COc1ccc(C[n](c2ccccc22)nc2-c(nc2Nc3ccncc3)ncc2OCC(F)(F)F)cc1 GUJXAQIBCNRTSK-UHFFFAOYSA-N 0.000 description 1
- YJIDUHCAIKNJAB-UHFFFAOYSA-N COc1cnc(-c2n[n](Cc(c(F)cc(OCCI)c3)c3F)c3ccccc23)nc1Nc1ccncc1 Chemical compound COc1cnc(-c2n[n](Cc(c(F)cc(OCCI)c3)c3F)c3ccccc23)nc1Nc1ccncc1 YJIDUHCAIKNJAB-UHFFFAOYSA-N 0.000 description 1
- DMXVTEHGWUYDJP-UHFFFAOYSA-N NC(c(c(O)c1)cnc1-c1n[n](Cc2ccccc2F)c2ccccc12)=O Chemical compound NC(c(c(O)c1)cnc1-c1n[n](Cc2ccccc2F)c2ccccc12)=O DMXVTEHGWUYDJP-UHFFFAOYSA-N 0.000 description 1
- VQVZFTCKLCNMID-UHFFFAOYSA-N NC1(CO)C=[O]C1 Chemical compound NC1(CO)C=[O]C1 VQVZFTCKLCNMID-UHFFFAOYSA-N 0.000 description 1
- HBGXGFLFLLDTML-UHFFFAOYSA-N NC1(CO)COC1 Chemical compound NC1(CO)COC1 HBGXGFLFLLDTML-UHFFFAOYSA-N 0.000 description 1
- KXMGOMFIWPNTDA-UHFFFAOYSA-N O=C1Nc2cc(CBr)ccc2CC1 Chemical compound O=C1Nc2cc(CBr)ccc2CC1 KXMGOMFIWPNTDA-UHFFFAOYSA-N 0.000 description 1
- JAXQPBINKGFTPK-UHFFFAOYSA-N OCC1(CO)CNC1 Chemical compound OCC1(CO)CNC1 JAXQPBINKGFTPK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
- A01H6/36—Ericaceae, e.g. azalea, cranberry or blueberry
- A01H6/368—Vaccinium, e.g. cranberry, blueberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physiology (AREA)
- Botany (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Extrusion Moulding Of Plastics Or The Like (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11184061.7 | 2011-10-06 | ||
| EP11184061 | 2011-10-06 | ||
| PCT/EP2012/069562 WO2013050438A1 (en) | 2011-10-06 | 2012-10-04 | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103974948A CN103974948A (zh) | 2014-08-06 |
| CN103974948B true CN103974948B (zh) | 2017-07-28 |
Family
ID=46968229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280059851.2A Expired - Fee Related CN103974948B (zh) | 2011-10-06 | 2012-10-04 | 在治疗过度增殖性疾病中用作bub1激酶抑制剂的取代的苄基吲唑 |
Country Status (38)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| CN104125957B (zh) | 2011-12-21 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的苄基吡唑 |
| EP2847180B1 (en) * | 2012-05-11 | 2017-01-04 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| CA2907730A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted indazoles |
| EP2976336A1 (en) * | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| US20160046604A1 (en) * | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| US9745285B2 (en) | 2013-06-21 | 2017-08-29 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP2016522231A (ja) * | 2013-06-21 | 2016-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | ジアミノヘテロアリール置換ピラゾール類 |
| EP3010911A1 (en) * | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| WO2014202590A1 (en) * | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| WO2014202583A1 (en) * | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| CN105764893A (zh) * | 2013-10-30 | 2016-07-13 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| TW201613886A (en) * | 2014-06-17 | 2016-04-16 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| WO2016042081A1 (en) * | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| CA2961578A1 (en) * | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| WO2016042084A1 (en) * | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 inhibitors |
| CA2961570A1 (en) * | 2014-09-19 | 2016-03-24 | Lars Barfacker | Benzyl substituted indazoles |
| GB201419264D0 (en) * | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| CN107406417B (zh) | 2015-01-28 | 2020-06-09 | 拜耳制药股份公司 | 4H-吡咯并[3,2-c]吡啶-4-酮衍生物 |
| JP6549735B2 (ja) * | 2015-06-09 | 2019-07-24 | アッヴィ・インコーポレイテッド | 核内受容体調節剤 |
| CN107922389A (zh) * | 2015-06-17 | 2018-04-17 | 拜耳制药股份公司 | 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮 |
| EP3390401A1 (en) * | 2015-12-16 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| KR102328682B1 (ko) | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| KR102048050B1 (ko) * | 2019-08-29 | 2020-01-22 | 대한민국 | Adb-푸비나카의 대사체 합성 방법 |
| CN110684016A (zh) * | 2019-09-27 | 2020-01-14 | 上海应用技术大学 | 一种含氟的azd9291衍生物及其制备方法和应用 |
| MX2023003362A (es) | 2020-09-23 | 2023-05-30 | Scorpion Therapeutics Inc | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2024254298A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| EP4724150A1 (en) | 2023-06-08 | 2026-04-15 | Antares Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010111624A (ja) * | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5470862A (en) | 1995-02-03 | 1995-11-28 | Ohmeda Pharmaceutical Products Division Inc. | Substituted pyrazolyl compounds and methods employing such compounds |
| ATE431347T1 (de) | 1996-10-14 | 2009-05-15 | Bayer Healthcare Ag | Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen |
| DE19834047A1 (de) * | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19846514A1 (de) * | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| JP4286146B2 (ja) | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| US7166293B2 (en) | 2002-03-29 | 2007-01-23 | Carlsbad Technology, Inc. | Angiogenesis inhibitors |
| WO2004024159A1 (en) | 2002-09-10 | 2004-03-25 | Scios Inc. | INHIBITORS OF TFGβ |
| DE10244810A1 (de) | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| US8748601B2 (en) | 2003-04-11 | 2014-06-10 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
| US20080242681A1 (en) | 2004-01-22 | 2008-10-02 | Altana Pharma Ag | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors |
| WO2007065010A2 (en) * | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| WO2008141731A2 (en) | 2007-05-18 | 2008-11-27 | Bayer Healthcare Ag | Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| WO2010069966A1 (en) | 2008-12-18 | 2010-06-24 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| CN102666537A (zh) | 2009-10-20 | 2012-09-12 | 艾格尔生物制药股份有限公司 | 治疗黄病毒科病毒感染的氮杂吲唑 |
| DK3415515T3 (da) | 2009-11-27 | 2020-03-16 | Adverio Pharma Gmbh | Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| SG10201502484SA (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
| TWI532737B (zh) | 2010-06-30 | 2016-05-11 | 艾諾屋製藥公司 | 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物 |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| CN104125957B (zh) | 2011-12-21 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的苄基吡唑 |
| CA2861804C (en) | 2011-12-27 | 2021-10-26 | Ironwood Pharmaceuticals, Inc. | 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators |
| EP2847180B1 (en) | 2012-05-11 | 2017-01-04 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| WO2014047111A1 (en) | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| EP2897953B8 (en) | 2012-09-19 | 2019-06-26 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
| US9738610B2 (en) | 2012-09-24 | 2017-08-22 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
| EP2976336A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| CA2907730A1 (en) | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted indazoles |
| US20160046604A1 (en) | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| EP3010911A1 (en) | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP2016522231A (ja) | 2013-06-21 | 2016-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | ジアミノヘテロアリール置換ピラゾール類 |
| WO2014202590A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| US9745285B2 (en) | 2013-06-21 | 2017-08-29 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| WO2014202583A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| CN105764893A (zh) | 2013-10-30 | 2016-07-13 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| CA2961578A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| WO2016042084A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 inhibitors |
| CA2961570A1 (en) | 2014-09-19 | 2016-03-24 | Lars Barfacker | Benzyl substituted indazoles |
| WO2016042081A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
-
2012
- 2012-04-10 UA UAA201404803A patent/UA111754C2/uk unknown
- 2012-10-04 CN CN201280059851.2A patent/CN103974948B/zh not_active Expired - Fee Related
- 2012-10-04 AP AP2014007533A patent/AP3847A/en active
- 2012-10-04 EA EA201400412A patent/EA201400412A1/ru unknown
- 2012-10-04 CA CA2851037A patent/CA2851037A1/en not_active Abandoned
- 2012-10-04 DK DK12766997.6T patent/DK2763982T3/en active
- 2012-10-04 SG SG11201400616YA patent/SG11201400616YA/en unknown
- 2012-10-04 HU HUE12766997A patent/HUE037154T2/hu unknown
- 2012-10-04 SI SI201231274T patent/SI2763982T1/en unknown
- 2012-10-04 AU AU2012320582A patent/AU2012320582B2/en not_active Ceased
- 2012-10-04 BR BR112014008045A patent/BR112014008045A2/pt not_active Application Discontinuation
- 2012-10-04 EP EP12766997.6A patent/EP2763982B1/en active Active
- 2012-10-04 LT LTEP12766997.6T patent/LT2763982T/lt unknown
- 2012-10-04 MX MX2014004122A patent/MX361279B/es active IP Right Grant
- 2012-10-04 NO NO12766997A patent/NO2763982T3/no unknown
- 2012-10-04 PT PT127669976T patent/PT2763982T/pt unknown
- 2012-10-04 PE PE2014000471A patent/PE20141203A1/es active IP Right Grant
- 2012-10-04 HR HRP20180546TT patent/HRP20180546T1/hr unknown
- 2012-10-04 WO PCT/EP2012/069562 patent/WO2013050438A1/en not_active Ceased
- 2012-10-04 RS RS20180403A patent/RS57099B1/sr unknown
- 2012-10-04 PH PH1/2014/500758A patent/PH12014500758A1/en unknown
- 2012-10-04 US US14/350,160 patent/US20140249133A1/en active Granted
- 2012-10-04 PL PL12766997T patent/PL2763982T3/pl unknown
- 2012-10-04 KR KR1020147011914A patent/KR102007056B1/ko not_active Expired - Fee Related
- 2012-10-04 ES ES12766997.6T patent/ES2665036T3/es active Active
- 2012-10-04 JP JP2014533880A patent/JP6140170B2/ja not_active Expired - Fee Related
- 2012-10-05 AR ARP120103719A patent/AR088449A1/es unknown
- 2012-10-05 UY UY0001034374A patent/UY34374A/es not_active Application Discontinuation
- 2012-10-05 TW TW101137035A patent/TWI588141B/zh not_active IP Right Cessation
-
2014
- 2014-03-19 IL IL231591A patent/IL231591A/en active IP Right Grant
- 2014-04-04 DO DO2014000062A patent/DOP2014000062A/es unknown
- 2014-04-04 CO CO14073129A patent/CO6930363A2/es active IP Right Grant
- 2014-04-04 GT GT201400063A patent/GT201400063A/es unknown
- 2014-04-04 CR CR20140161A patent/CR20140161A/es unknown
- 2014-04-04 EC ECSP14013284 patent/ECSP14013284A/es unknown
- 2014-04-04 CU CUP2014000043A patent/CU20140043A7/es unknown
- 2014-04-04 TN TNP2014000138A patent/TN2014000138A1/en unknown
-
2017
- 2017-02-21 US US15/438,254 patent/US10266548B2/en not_active Expired - Fee Related
-
2018
- 2018-04-10 CY CY20181100391T patent/CY1120318T1/el unknown
-
2019
- 2019-03-21 US US16/360,811 patent/US10604532B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010111624A (ja) * | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
Non-Patent Citations (1)
| Title |
|---|
| Structure and Substrate Recruitment of the Human Spindle Checkpoint Kinase Bub1;Jungseog Kang et al.;《Molecular Cell》;20081107;第32卷;第394-405页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10604532B2 (en) | Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases | |
| CN104125957B (zh) | 取代的苄基吡唑 | |
| CN104411701B (zh) | 作为Bub1抑制剂的用于治疗癌症的取代的环烯并吡唑 | |
| CN101765596B (zh) | 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂 | |
| CN105452237A (zh) | 杂芳基取代的吡唑 | |
| HK1223350A1 (zh) | 杂芳基取代的吲唑 | |
| TW201514166A (zh) | 經雜芳基取代之吲唑 | |
| CN105408324A (zh) | 取代的苄基吡唑 | |
| CN105051030A (zh) | 二氨基杂芳基取代的吲唑 | |
| CN105473570A (zh) | 二氨基杂芳基取代的吡唑 | |
| HK1200449B (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
| NZ623098B2 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
| HK1203196B (en) | Substituted benzylpyrazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1200449 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1200449 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170728 Termination date: 20201004 |